Investing Ideas
/
Australian Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows

Australian Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.

2 companies

	Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
	TLX Telix Pharmaceuticals	AU$30.12	11.2%	186.3%	AU$10.1b	AU$27.48	PE203.3x	E33.3%	n/a
	TRJ Trajan Group Holdings	AU$0.80	-3.6%	-34.4%	AU$121.9m	AU$1.45	PS0.8x	E98.8%	n/a

Page 1 of 1